It is currently Sat Feb 28, 2015 4:39 pm

News News of Drug Pipeline

Site map of Drug Pipeline » Forum : Drug Pipeline

A board to discuss future MS therapies in early stage (Phase I or II) trials.

Patient enrolment completed in first study of olesoxime

Patient enrolment completed in first study of olesoxime in relapsing remitting MS

Trophos SA announced today that they have completed enrollment in the Translate MS-Repair Phase Ib multiple sclerosis (MS) trial.

The trial is a randomized, placebo controlled, Phase Ib study in multiple sclerosis (MS) patients treated with Trophos' olesoxime as an add-on therapy to Interferon beta. In three months, 44 patients have been recruited in three investigational sites in France. The first subject was ...
Read more : Patient enrolment completed in first study of olesoxime | Views : 671 | Replies : 0

Botox for MS Hug

Has anybody tried Botox injections for the MS Hug ? Was it successful or not ?
Read more : Botox for MS Hug | Views : 692 | Replies : 1

Initiation of a cooperative phase 2b trial of MN-166

Initiation of a cooperative phase 2b trial of MN-166 in progressive MS announced

MediciNova, Inc.announced the funding and regulatory approvals of a NIH-based grant for a Phase 2b trial of MN-166 (ibudilast) in subjects with progressive multiple sclerosis (progressive MS). The principal investigator will be Robert Fox, M.D., M.S., FAAN, Staff Neurologist at the Mellen Center for Multiple Sclerosis at Cleveland Clinic.

The grant is for a funded cooperative effort by the NeuroNEXT clinical trial ...
Read more : Initiation of a cooperative phase 2b trial of MN-166 | Views : 581 | Replies : 0

Myelin peptide transdermal patch

Small Study Suggests Possible Benefit for Skin Patch to Reduce Immune Activity in Multiple Sclerosis ... x?nid=8012

Polish researchers reported results of a small clinical trial in which a skin patch containing myelin peptides (portions of the substance that insulates nerve fibers and is a target of the immune attack on the brain and spinal cord in MS) were administered to 20 people with relapsing-remitting MS via a ...
Read more : Myelin peptide transdermal patch | Views : 1527 | Replies : 3


Etifoxine to target, a protein referred to as mitochondrial translocator protein (TSPO), had been previously identified but not linked to MS, an autoimmune disease that strips the protective fatty coating off nerve fibers of the brain and spinal cord.
Read more : Etifoxine | Views : 698 | Replies : 0

Patient enrollment in AVP-923 PRIME Study completed

Avanir Pharmaceuticals, Inc. announced completion of patient enrollment in the company's phase II, placebo controlled study testing three doses of AVP-923 for the treatment of central neuropathic pain in multiple sclerosis. Top-line results from this study are expected in the fourth calendar quarter of 2013.

"Final completion of enrollment in PRIME is an important milestone in the AVP-923 development pathway," said Joao Siffert, MD, chief scientific officer at Avanir. "We are looking forward to the ...
Read more : Patient enrollment in AVP-923 PRIME Study completed | Views : 714 | Replies : 0



I just created a new petition and I hope you can sign -- it's called: Multiple Sclerosis as an „invented diseease“ by Big Pharma – many billions dollars gains yearly! Stop this nonsense!

This issue is very important to me, and I’m trying to get to 100 signatures and could use your help.

Read more about it and sign it here: ... ?Day2Share

Campaigns like this always ...
Read more : HELP ! | Views : 801 | Replies : 2

Hi friends my name is seeva and i found the above drug a treatment for M.S in the USA any one knowmore about this methotrxate using for treating M.S in Australia. My old neuro.treat me with a chemo drug called mitoxantrone in 1999 in Sydney and was very effective for me. when i was bound in Wheelchair my old neuro gave me this chemo drug by ...
Read more : RE INTRATHECAL METHOTREXATE TREATMENT FOR M.S | Views : 728 | Replies : 2

Pegylated Interferon

News from the NMSS... ... x?nid=7305

Updated May 21, 2013: Based on the results reported below, Biogen Idec announced in a May 21 press release that it has submitted an application to the FDA for approval of peginterferon beta-1a for the treatment of relapsing forms of MS.

Biogen Idec announced that a phase III study of peginterferon beta-1a, injected under the skin either every two or four weeks, ...
Read more : Pegylated Interferon | Views : 724 | Replies : 2


Login  •  Register


Total posts 223876 • Total topics 23317 • Total members 14752

Contact us | Terms of Service